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In this issue of Immunity, Ma et al. (2013) demonstrate that neoplastic cell release of ATP drives recruitment
and differentiation of CD11b+ dendritic cells within tumors, where their ability to locally present antigen
improves response to anthracycline-based chemotherapy.The majority of cancer patients are
treated with chemotherapy (CTX) at
some stage of their disease. Ostensibly
targeting proliferating neoplastic cells,
chemotherapeutics also profoundly affect
immune cells that, at least in part, also
regulate therapeutic efficacy (Zitvogel
et al., 2011). Although chemotherapeutics
can induce transient lymphopenia and
other systemic changes, certain classes
such as anthracyclines are known to
induce immunogenic cell death (ICD)
and are dependent on intratumoral CD8+
T cells for efficacy in some murine tumor
models, with clinical data also supporting
this association (Zitvogel et al., 2011).
Much of themolecular underpinnings of
CTX-induced ICD have been delineated
through a series of studies by the Zitvogel
and Kroemer groups. Collectively, studies
from these researchers indicate that ICD
requires pericellular exposure of calreticu-
lin to promote engulfment by antigen-pre-
senting cells (APCs), release of unmodi-
fied high-mobility group box 1 (HMGB1)
and ATP, and subsequent induction of
dendritic cell (DC) activation by binding
to Toll-like receptor 4 (TLR4) and the puri-
nergic receptor P2RX7, respectively.
Presumably, activated Batf3-dependent
CD103+ DCs then migrate to draininglymph nodes and activate antigen-spe-
cific CD8+ T cells, leading to enhanced
CD8+ T cell infiltration approximately
7 days after CTX (Ma et al., 2011). How-
ever, also observed in subcutaneous
murine tumor models is secretion of inter-
leukin-1b (IL-1b) by DCs and recruitment
of IL-17A expressing gd T cells, both of
whicharecritical for response toanthracy-
clines (Ma et al., 2011), thus indicating an
important role for the tumormicroenviron-
ment in mediating CTX response. Now,
Zitvogel and Ma extend upon their previ-
ous studies and investigate antigen pre-
sentation following anthracyline therapy,
revealing local presentation of tumor
antigen by CD11c+CD11b+CD103+Ly6Chi
DCs as being critical for limiting tumor
growth through promotion of CD8+ T cell
responses (Figure 1).
In this issue of Immunity, Ma et al.
(2013) first examined the presence of
phagocytes in tumors after treatment
with CTX (the anthracyclines mitoxan-
trone or doxorubicin) and observed accu-
mulation of F4/80+CD169+ macrophages
and CD11b+Ly6G+ granulocytes 48 hr af-
ter CTX, with increases in CD11c+CD86+
DCs as early as 12 hr posttreatment. Early
accumulation of DCs was driven by ATP
release because no increase in myeloidcells was observed when neoplastic cells
were transfected with the ecto-ATPase
CD39 or when tumors were transplanted
into mice lacking the purinergic receptor
P2Y2, known to direct monocyte chemo-
taxis toward apoptotic cells (Chekeni
et al., 2010).
To addresswhethermyeloid cell infiltra-
tion was driven by enhanced recruitment,
altered differentiation, or both, the authors
first evaluated total leukocyte presence
following CTX. Whereas no kinetic differ-
ence in reconstitution by CD45.2+ cells
following whole-tumor transfer from
CD45.1 hosts was observed, a significant
increase in CD11b+ myeloid cells with a
CD34+c-Kit+Sca1CD16/32+ progenitor
phenotype in anthracycline-treated tu-
mors was revealed. Colony formation
was confined to theCD11b+Ly6Chi subset
of these cells, which expanded roughly 2-
fold in treated tumors and generated a
3-fold increase in colony formation on a
per-cell basis as compared to CTX-naive
controls. In vivo, Ly6Chi cells isolated
from anthracycline-treated tumors pre-
dominantly differentiated into Ly6G+
granulocytes, consistent with results from
other investigators (Youn et al., 2013). In
contrast, cells that were adoptively trans-
ferred into tumor-bearing mice treated
anthracyclines
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Figure 1. Intratumoral Antigen Presentation by CD11b+Ly6C+ DCs following Anthracycline-
Induced ICD
Anthracyclines induce ICD in sensitive cells, leading to release of ATP and recruitment of CD11b+Ly6C+
inflammatory monocytes via purinergic receptors. ATP also promotes DC differentiation, and following
antigen uptake and activation via the interaction between HMGB1 and TLR4, CD11b+Ly6C+ DCs remain
in the tumor and are able to promote a local CD8+ T cell response.
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maintain Ly6C expression and differen-
tiate into CD11b+CD11c+MHCII+ DCs.
This in vivo observation was recapitulated
in vitro by using anthracycline-treated,
but not untreated, tumor cells in conjunc-
tion with GM-CSF and IL-4. Critically,
both DC differentiation and, to a lesser
extent, progenitor recruitment were
dependent on presence of extracellular
ATP, thereby linking both events to
myeloid cell accumulation following
anthracycline CTX.
In addition, by preventing myeloid cell
accumulation, CD39 expression ablated
the response of tumors to anthracyclines,
indicating that one of the recruited popu-
lations was critical for promoting the
CD8+ T cell-dependent response. Consis-
tent with this, uptake of tumor antigens,
as measured through use of eGFP-
expressing tumors, was localized to
CD11b+ cells, and an anti-CD11b mono-
clonal antibody prevented response to
doxorubicin in multiple tumor models.
Whereas all myeloid subsets tended to
localize closer to dying neoplastic cells
and were able to take up eGFP, only
CD11b+CD11c+Ly6Chi cells from oval-
bumin (OVA)-expressing tumors treated
with doxorubicin were able to activate
OVA-specific CD8+ T cell to express
high levels of interferon-g (IFN-g) and/orIL-2. Moreover, treatment with the puri-
nergic receptor inhibitor suramin pre-
vented recruitment of DCs, but not
macrophages, and yet still ablated tumor
response to mitoxantrone. Although
suramin also blocked granulocyte
recruitment, these cells were unable to
stimulate a T cell response and their
depletion with an anti-Ly6G antibody
onlyminimally reduced theCTX response.
Thus, only CD11b+CD11c+Ly6Chi DCs
were able to uptake tumor antigen,
activate an antigen-specific CD8+ T cell
response, and mediate the in vivo
response to CTX.
Although the CD11b+CD11c+Ly6Chi
DCs described by Ma et al. did not
express CD205, they were ubiquitously
positive for CD103. CD11b and CD103
are normally expressed by unique DC
populations with coexpression only noted
under homeostatic conditions in the
lamina propria and mesenteric lymph
nodes. Interestingly, CD11c+CD11b+
CD103+ DCs, unlike other DC populations
expressing CD103 and/or CD8a, are
not dependent on Batf3 expression
(Edelson et al., 2010). Consistent with
this, Ma et al. observed no reduction in
CD11b+CD11c+ DCs in Batf3/ mice.
Batf3/ mice also displayed a normal
response to doxorubicin, indicating that
the usual subsets of DCs involved inImmunitycross-presentation were dispensable for
mediating T cell activation in these
models.
Whereas CD103+ DCs are typically
considered to be the more important
migratory subset for CD8+ T cell antigen
presentation, both CD11b+ dermal DCs
and CD11b+CD103+ lamina propria DCs
migrate to draining lymph nodes and can
be critical for mediating immune re-
sponses, depending on the inflammatory
or infection model being examined. Ma
et al. did not perform a comprehensive
analysis of lymph node trafficking by
tumor DCs; however, resection of the
draining lymph nodes, either before tumor
implantation or 1 day post-CTX, did not
alter the chemotherapeutic response.
Even in the absence of draining lymph
nodes, doxorubicin treatment increased
the percentage of activated CD69+CD8+
T cells and promoted proliferation of
adoptively transferred OT-I cells within
OVA-expressing tumors. That said, these
data do not rule out antigen presentation
occurring in other lymphoid organs.
For example, neutrophils were recently
described to transmit antigen from the
dermis to the bone marrow during viral
infection (Duffy et al., 2012), and neutro-
phil depletion did partially diminish tumor
response to doxorubicin. However, it
seems unlikely that DCs, necessary for
the chemotherapeutic response, would
also be so promiscuous. Although addi-
tional studies are certainly warranted,
Ma et al. provide an indication that local
antigen presentation by CD11c+CD11b+
CD103+Ly6Chi DCs is critical for regu-
lating antitumor immune responses, at
least in the context of response to
anthracyclines.
Going forward, it will be important to
identify how applicable the findings in
Ma et al. are to other tumor models, espe-
cially those in orthotopic locales and in de
novo primary and metastatic tumors,
considering that in some tumor models
absence of adaptive immunity is without
consequence with regards to doxorubicin
or other CTXs known to induce ICD
(Ciampricotti et al., 2012). This discrep-
ancy may be explained in part by
enhanced immune suppression within
tumor parenchyma (DeNardo et al.,
2011). However, it will be important to
determine whether the CD11c+CD11b+
CD103+Ly6Chi DC subset described
in Ma et al. is observed in tumors38, April 18, 2013 ª2013 Elsevier Inc. 627
Immunity
Previewsfrom other tissues or similar tumors
initiated by other oncgenic-driver muta-
tions, as well as whether this specific
population or simply monocyte-derived
CD11b+ inflammatory DCs in general are
important.
Several immune-based therapies have
recently been approved for clinical use,
primarily for refractory metastatic dis-
ease, with many clinical trials underway
examining efficacy at earlier stages in
conjunction with standard-of-care CTX.
As noted by the authors, it remains un-
clear whether CTX alone can elicit a de
novo T cell response or instead is reacti-
vating a suppressed response that, in
conjunction with the enhanced suscepti-
bility of CTX-treated tumor cells to killing
by granzyme B, is able to limit tumor
growth (Ramakrishnan et al., 2010). Iden-628 Immunity 38, April 18, 2013 ª2013 Elsevtifying which of these possibilities is
accuratemay assist with the development
of future immune-based therapies in the
clinical arena.
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Why patients with chronic kidney disease have elevated cardiovascular risk remains elusive. In this issue
of Immunity, Speer et al. (2013) show that natural modification of high density lipoprotein promotes hyperten-
sion through a toll-like receptor-dependent mechanism.Chronic kidney disease (CKD) afflicts mil-
lions of people, with the majority of these
patients eventually dying, not from renal
failure but from accelerated cardiovas-
cular disease (CVD). Notably, although
this population suffers from comorbid
conditions known to increase CVD risk,
such as diabetes and hypertension, their
dramatically increased cardiovascular
mortality cannot be fully explained by
these and other ‘‘traditional’’ risk factors,
such as age, gender, smoking, choles-
terol levels, obesity, and physical inac-
tivity (Beddhu et al., 2007). Animal models
are concordant with the clinical data. For
example, when renal disease is intro-
duced into mouse models, there is accel-erated progression or impaired regression
of atherosclerosis (e.g., Ponda et al.,
2010).
While practitioners await progress in
filling in the gaps in the mechanisms
underlying the increased risk of CVD in
CKD patients, current therapy necessarily
is based on regimens used in the general
population. Unfortunately, the risk reduc-
tion is frequently below that achieved in
non-CKD patients, which already is sub-
optimal. For example, in hemodialysis
patients, statins are able to impressively
lower low density lipoprotein (LDL)
cholesterol, but unlike other at-risk popu-
lations who are expected to have 30%–
40% reductions in CVD events, thesepatients do not experience improved
survival.
This incomplete success of current
clinical therapies in the general popula-
tion, as well as in those with specific sub-
populations, such as those with CKD, has
called attention to the potential role of
HDL, the so-called ‘‘good cholesterol’’ to
reduce the substantial level of residual
CVD risk. The basis for this hope, as we
recently reviewed (Hewing et al., 2012),
has been numerous observational studies
that have demonstrated an inverse rela-
tionship between levels of HDL-choles-
terol (HDL-C) and CVD risk. Yet a spate
of recent studies, both genetic and
interventional, has raised the issue that
